Your browser doesn't support javascript.
loading
Community outbreak of serogroup B invasive meningococcal disease in Beaujolais, France, February to June 2016: from alert to targeted vaccination.
Thabuis, Alexandra; Tararbit, Karim; Taha, Muhamed-Kheir; Dejour-Salamanca, Dominique; Ronin, Vincent; Parent du Chatelet, Isabelle; Spaccaferri, Guillaume.
Afiliação
  • Thabuis A; Santé publique France, French national public health agency, Cellule d'intervention en région Auvergne-Rhône-Alpes, Saint-Maurice, France.
  • Tararbit K; Agence régionale de santé Auvergne-Rhône-Alpes, Regional health agency, Lyon, France.
  • Taha MK; Institut Pasteur, National Reference Centre for Meningococci, Paris, France.
  • Dejour-Salamanca D; Agence régionale de santé Auvergne-Rhône-Alpes, Regional health agency, Lyon, France.
  • Ronin V; Agence régionale de santé Auvergne-Rhône-Alpes, Regional health agency, Lyon, France.
  • Parent du Chatelet I; Santé publique France, French national public health agency, Department of Infectious Diseases, Saint-Maurice, France.
  • Spaccaferri G; Santé publique France, French national public health agency, Cellule d'intervention en région Auvergne-Rhône-Alpes, Saint-Maurice, France.
Euro Surveill ; 23(28)2018 07.
Article em En | MEDLINE | ID: mdl-30017022
ABSTRACT
In February and March 2016, four cases of serogroup B invasive meningococcal disease (IMD) occurred over 3 weeks in a small area north of Lyon in the Auvergne-Rhône-Alpes region, France. There were no deaths but two cases had sequelae. This community outbreak was caused by a rare meningococcal strain of the clonal complex ST-32, covered by the 4CMenB/Bexsero vaccine. The incidence rate for serogroup B IMD in this area was 22.5 per 100,000 inhabitants, which is above the epidemic threshold (10/100,000). The number of cases observed was significantly higher than expected in the age group of 0-24 year-olds (standardised incidence ratio 96). These results suggested the potential emergence of this invasive strain in this sub-population. In accordance with French recommendations, it was decided to vaccinate the population aged between 2 months and 24 years, living, working or studying in the epidemic area. The vaccination campaign took place from April to September 2016. Vaccination coverage was estimated at 47% for one dose and 40% for two doses. The lowest coverage estimations were observed for the age groups younger than 3 and 15-19 years. Enhanced epidemiological and microbiological surveillance reported a fifth case in June 2016, outside the epidemic area.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Surtos de Doenças / Vacinação / Controle de Infecções / Vacinas Meningocócicas / Neisseria meningitidis Sorogrupo B / Cobertura Vacinal / Infecções Meningocócicas Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Surtos de Doenças / Vacinação / Controle de Infecções / Vacinas Meningocócicas / Neisseria meningitidis Sorogrupo B / Cobertura Vacinal / Infecções Meningocócicas Idioma: En Ano de publicação: 2018 Tipo de documento: Article